European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society

R. A C Hughes, P. Bouche, D. R. Cornblath, E. Evers, R. D M Hadden, A. Hahn, I. Illa, C. L. Koski, J. M. Léger, E. Nobile-Orazio, J. Pollard, C. Sommer, P. Van Den Bergh, P. A. Van Doorn, I. N. Van Schaik

Research output: Contribution to journalArticle

Abstract

Numerous sets of diagnostic criteria have sought to define chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and randomized trials and systematic reviews of treatment have been published. The objective is to prepare consensus guidelines on the definition, investigation and treatment of CIDP. Disease experts and a patient representative considered references retrieved from MEDLINE and Cochrane Systematic Reviews in May 2004 and prepared statements which were agreed in an iterative fashion. The Task Force agreed on good practice points to define clinical and electrophysiological diagnostic criteria for CIDP with or without concomitant diseases and investigations to be considered. The principal treatment recommendations were: (1) intravenous immunoglobulin (IVIg) or corticosteroids should be considered in sensory and motor CIDP (level B recommendation); (2) IVIg should be considered as the initial treatment in pure motor CIDP (Good Practice Point); (3) if IVIg and corticosteroids are ineffective plasma exchange (PE) should be considered (level A recommendation); (4) If the response is inadequate or the maintenance doses of the initial treatment are high, combination treatments or adding an immunosuppressant or immunomodulatory drug should be considered (Good Practice Point); (5) Symptomatic treatment and multidisciplinary management should be considered (Good Practice Point).

Original languageEnglish
Pages (from-to)326-332
Number of pages7
JournalEuropean Journal of Neurology
Volume13
Issue number4
DOIs
Publication statusPublished - Apr 2006

Fingerprint

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Advisory Committees
Joints
Guidelines
Intravenous Immunoglobulins
Therapeutics
Adrenal Cortex Hormones
Patient Advocacy
Plasma Exchange
Immunosuppressive Agents
MEDLINE

Keywords

  • Chronic inflammatory demyelinating polyradiculoneuropathy
  • Guideline
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. / Hughes, R. A C; Bouche, P.; Cornblath, D. R.; Evers, E.; Hadden, R. D M; Hahn, A.; Illa, I.; Koski, C. L.; Léger, J. M.; Nobile-Orazio, E.; Pollard, J.; Sommer, C.; Van Den Bergh, P.; Van Doorn, P. A.; Van Schaik, I. N.

In: European Journal of Neurology, Vol. 13, No. 4, 04.2006, p. 326-332.

Research output: Contribution to journalArticle

Hughes, R. A C ; Bouche, P. ; Cornblath, D. R. ; Evers, E. ; Hadden, R. D M ; Hahn, A. ; Illa, I. ; Koski, C. L. ; Léger, J. M. ; Nobile-Orazio, E. ; Pollard, J. ; Sommer, C. ; Van Den Bergh, P. ; Van Doorn, P. A. ; Van Schaik, I. N. / European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. In: European Journal of Neurology. 2006 ; Vol. 13, No. 4. pp. 326-332.
@article{79643bdee7424af4887502f2a930dbe0,
title = "European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society",
abstract = "Numerous sets of diagnostic criteria have sought to define chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and randomized trials and systematic reviews of treatment have been published. The objective is to prepare consensus guidelines on the definition, investigation and treatment of CIDP. Disease experts and a patient representative considered references retrieved from MEDLINE and Cochrane Systematic Reviews in May 2004 and prepared statements which were agreed in an iterative fashion. The Task Force agreed on good practice points to define clinical and electrophysiological diagnostic criteria for CIDP with or without concomitant diseases and investigations to be considered. The principal treatment recommendations were: (1) intravenous immunoglobulin (IVIg) or corticosteroids should be considered in sensory and motor CIDP (level B recommendation); (2) IVIg should be considered as the initial treatment in pure motor CIDP (Good Practice Point); (3) if IVIg and corticosteroids are ineffective plasma exchange (PE) should be considered (level A recommendation); (4) If the response is inadequate or the maintenance doses of the initial treatment are high, combination treatments or adding an immunosuppressant or immunomodulatory drug should be considered (Good Practice Point); (5) Symptomatic treatment and multidisciplinary management should be considered (Good Practice Point).",
keywords = "Chronic inflammatory demyelinating polyradiculoneuropathy, Guideline, Treatment",
author = "Hughes, {R. A C} and P. Bouche and Cornblath, {D. R.} and E. Evers and Hadden, {R. D M} and A. Hahn and I. Illa and Koski, {C. L.} and L{\'e}ger, {J. M.} and E. Nobile-Orazio and J. Pollard and C. Sommer and {Van Den Bergh}, P. and {Van Doorn}, {P. A.} and {Van Schaik}, {I. N.}",
year = "2006",
month = "4",
doi = "10.1111/j.1468-1331.2006.01278.x",
language = "English",
volume = "13",
pages = "326--332",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",

}

TY - JOUR

T1 - European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy

T2 - Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society

AU - Hughes, R. A C

AU - Bouche, P.

AU - Cornblath, D. R.

AU - Evers, E.

AU - Hadden, R. D M

AU - Hahn, A.

AU - Illa, I.

AU - Koski, C. L.

AU - Léger, J. M.

AU - Nobile-Orazio, E.

AU - Pollard, J.

AU - Sommer, C.

AU - Van Den Bergh, P.

AU - Van Doorn, P. A.

AU - Van Schaik, I. N.

PY - 2006/4

Y1 - 2006/4

N2 - Numerous sets of diagnostic criteria have sought to define chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and randomized trials and systematic reviews of treatment have been published. The objective is to prepare consensus guidelines on the definition, investigation and treatment of CIDP. Disease experts and a patient representative considered references retrieved from MEDLINE and Cochrane Systematic Reviews in May 2004 and prepared statements which were agreed in an iterative fashion. The Task Force agreed on good practice points to define clinical and electrophysiological diagnostic criteria for CIDP with or without concomitant diseases and investigations to be considered. The principal treatment recommendations were: (1) intravenous immunoglobulin (IVIg) or corticosteroids should be considered in sensory and motor CIDP (level B recommendation); (2) IVIg should be considered as the initial treatment in pure motor CIDP (Good Practice Point); (3) if IVIg and corticosteroids are ineffective plasma exchange (PE) should be considered (level A recommendation); (4) If the response is inadequate or the maintenance doses of the initial treatment are high, combination treatments or adding an immunosuppressant or immunomodulatory drug should be considered (Good Practice Point); (5) Symptomatic treatment and multidisciplinary management should be considered (Good Practice Point).

AB - Numerous sets of diagnostic criteria have sought to define chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and randomized trials and systematic reviews of treatment have been published. The objective is to prepare consensus guidelines on the definition, investigation and treatment of CIDP. Disease experts and a patient representative considered references retrieved from MEDLINE and Cochrane Systematic Reviews in May 2004 and prepared statements which were agreed in an iterative fashion. The Task Force agreed on good practice points to define clinical and electrophysiological diagnostic criteria for CIDP with or without concomitant diseases and investigations to be considered. The principal treatment recommendations were: (1) intravenous immunoglobulin (IVIg) or corticosteroids should be considered in sensory and motor CIDP (level B recommendation); (2) IVIg should be considered as the initial treatment in pure motor CIDP (Good Practice Point); (3) if IVIg and corticosteroids are ineffective plasma exchange (PE) should be considered (level A recommendation); (4) If the response is inadequate or the maintenance doses of the initial treatment are high, combination treatments or adding an immunosuppressant or immunomodulatory drug should be considered (Good Practice Point); (5) Symptomatic treatment and multidisciplinary management should be considered (Good Practice Point).

KW - Chronic inflammatory demyelinating polyradiculoneuropathy

KW - Guideline

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=33646035214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646035214&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1331.2006.01278.x

DO - 10.1111/j.1468-1331.2006.01278.x

M3 - Article

C2 - 16643309

AN - SCOPUS:33646035214

VL - 13

SP - 326

EP - 332

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 4

ER -